Partnership is an important part of EpimAb’s strategy to broaden our pipeline and strengthen the validation of our science. EpimAb’s technologies and assets are protected in major markets such as the United States by a strong portfolio of intellectual property, and we concluded multiple agreements with biopharmaceutical companies throughout the world granting several selected license arrangements to such IP.  EpimAb also could consider partnerships on assets from other companies with a strategic fit to our existing clinical portfolio.

To discuss any partnering opportunities, please feel free to send a mail to partnering@epimab.com